S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:RVNC

Revance Therapeutics Competitors

$26.26
+0.91 (+3.59 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.94
Now: $26.26
$26.73
50-Day Range
$25.35
MA: $28.17
$29.97
52-Week Range
$11.78
Now: $26.26
$34.62
Volume737,030 shs
Average Volume452,838 shs
Market Capitalization$1.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42

Competitors

Revance Therapeutics (NASDAQ:RVNC) Vs. SRPT, GWPH, ALLK, AVIR, TGTX, and BPMC

Should you be buying RVNC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Revance Therapeutics, including Sarepta Therapeutics (SRPT), GW Pharmaceuticals (GWPH), Allakos (ALLK), Atea Pharmaceuticals (AVIR), TG Therapeutics (TGTX), and Blueprint Medicines (BPMC).

Sarepta Therapeutics (NASDAQ:SRPT) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Sarepta Therapeutics and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million18.04$-715,080,000.00($9.71)-8.97
Revance Therapeutics$410,000.004,262.38$-159,430,000.00($3.67)-7.16

Revance Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Sarepta Therapeutics and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Risk and Volatility

Sarepta Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sarepta Therapeutics and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics181302.55
Revance Therapeutics01602.86

Sarepta Therapeutics currently has a consensus price target of $156.1905, suggesting a potential upside of 79.41%. Revance Therapeutics has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Revance Therapeutics.

Summary

Sarepta Therapeutics beats Revance Therapeutics on 9 of the 14 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares GW Pharmaceuticals and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million21.37$-9,020,000.00($0.24)-892.71
Revance Therapeutics$410,000.004,262.38$-159,430,000.00($3.67)-7.16

GW Pharmaceuticals has higher revenue and earnings than Revance Therapeutics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares GW Pharmaceuticals and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Risk and Volatility

GW Pharmaceuticals has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GW Pharmaceuticals and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Revance Therapeutics01602.86

GW Pharmaceuticals currently has a consensus price target of $197.3077, suggesting a potential downside of 7.91%. Revance Therapeutics has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. Given Revance Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Revance Therapeutics is more favorable than GW Pharmaceuticals.

Summary

GW Pharmaceuticals beats Revance Therapeutics on 8 of the 14 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Allakos and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-64.12
Revance Therapeutics$410,000.004,262.38$-159,430,000.00($3.67)-7.16

Allakos has higher earnings, but lower revenue than Revance Therapeutics. Allakos is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.4% of Allakos shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Allakos and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Risk and Volatility

Allakos has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Allakos and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00503.00
Revance Therapeutics01602.86

Allakos currently has a consensus price target of $181.50, suggesting a potential upside of 49.78%. Revance Therapeutics has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. Given Allakos' stronger consensus rating and higher probable upside, analysts plainly believe Allakos is more favorable than Revance Therapeutics.

Summary

Allakos beats Revance Therapeutics on 8 of the 13 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Profitability

This table compares Atea Pharmaceuticals and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Revance Therapeutics-5,818.87%-85.72%-44.85%

Insider & Institutional Ownership

74.4% of Revance Therapeutics shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Atea Pharmaceuticals and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Revance Therapeutics$410,000.004,262.38$-159,430,000.00($3.67)-7.16

Atea Pharmaceuticals has higher earnings, but lower revenue than Revance Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Atea Pharmaceuticals and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Revance Therapeutics01602.86

Atea Pharmaceuticals currently has a consensus price target of $58.3333, suggesting a potential downside of 22.59%. Revance Therapeutics has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. Given Revance Therapeutics' higher probable upside, analysts plainly believe Revance Therapeutics is more favorable than Atea Pharmaceuticals.

Summary

Revance Therapeutics beats Atea Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Revance Therapeutics (NASDAQ:RVNC) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Revance Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
TG Therapeutics-151,798.69%-223.96%-108.08%

Institutional & Insider Ownership

74.4% of Revance Therapeutics shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Revance Therapeutics and TG Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,262.38$-159,430,000.00($3.67)-7.16
TG Therapeutics$150,000.0038,368.78$-172,870,000.00($1.83)-23.92

Revance Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Revance Therapeutics and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics01602.86
TG Therapeutics00503.00

Revance Therapeutics currently has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 46.22%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Revance Therapeutics.

Volatility & Risk

Revance Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Summary

Revance Therapeutics beats TG Therapeutics on 8 of the 14 factors compared between the two stocks.

Revance Therapeutics (NASDAQ:RVNC) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Revance Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
Blueprint Medicines41.08%43.72%33.35%

Institutional & Insider Ownership

74.4% of Revance Therapeutics shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by insiders. Comparatively, 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Revance Therapeutics and Blueprint Medicines' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,262.38$-159,430,000.00($3.67)-7.16
Blueprint Medicines$66.51 million85.59$-347,690,000.00($7.27)-13.51

Revance Therapeutics has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Revance Therapeutics and Blueprint Medicines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics01602.86
Blueprint Medicines05912.73

Revance Therapeutics currently has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. Blueprint Medicines has a consensus price target of $111.7857, suggesting a potential upside of 13.81%. Given Revance Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Revance Therapeutics is more favorable than Blueprint Medicines.

Volatility & Risk

Revance Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Summary

Revance Therapeutics beats Blueprint Medicines on 8 of the 15 factors compared between the two stocks.


Revance Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$87.06+2.1%$6.87 billion$380.83 million-11.13Upcoming Earnings
Analyst Report
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$214.25+0.3%$6.65 billion$311.33 million-124.56Decrease in Short Interest
Analyst Revision
Allakos logo
ALLK
Allakos
1.7$121.18+2.4%$6.36 billionN/A-44.23Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
AVIR
Atea Pharmaceuticals
1.7$75.36+7.9%$6.23 billionN/A0.00Decrease in Short Interest
Gap Down
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$43.77+0.6%$5.76 billion$150,000.00-20.65Upcoming Earnings
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$98.22+2.2%$5.69 billion$66.51 million18.12Analyst Report
News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$117.91+0.8%$5.68 billionN/A-33.59Upcoming Earnings
Analyst Downgrade
Perrigo logo
PRGO
Perrigo
2.6$40.36+1.0%$5.51 billion$4.84 billion-672.55Upcoming Earnings
Dividend Increase
High Trading Volume
Unusual Options Activity
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$32.52+1.0%$5.48 billionN/A0.00Upcoming Earnings
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$82.60+3.1%$5.40 billion$1.00 billion-12.52Analyst Upgrade
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$96.00+1.2%$5.12 billion$1.11 billion30.87Analyst Upgrade
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.4$84.98+2.2%$5.09 billionN/A-6.93Upcoming Earnings
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.35+1.1%$4.85 billion$806.43 million-11.38Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21+0.0%$4.75 billion$26.69 million-46.12News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$67.84+2.9%$4.70 billion$36.13 million-101.25Upcoming Earnings
Decrease in Short Interest
Gap Up
FibroGen logo
FGEN
FibroGen
1.4$50.03+0.3%$4.55 billion$256.58 million-19.17Upcoming Earnings
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$85.00+1.8%$4.42 billion$6.87 million-8.21Earnings Announcement
Analyst Report
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
IMAB
I-Mab
0.9$59.19+1.2%$4.26 billion$4.31 million-2.05Analyst Report
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$28.74+3.7%$4.18 billion$204.89 million-35.93Upcoming Earnings
News Coverage
Gap Down
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$122.26+0.8%$4.17 billion$26.52 million-10.77Upcoming Earnings
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$22.69+1.1%$4.07 billion$114.62 million-9.15Earnings Announcement
Analyst Revision
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$57.10+3.3%$3.90 billion$306.98 million-8.17Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Arvinas logo
ARVN
Arvinas
2.0$78.30+5.6%$3.79 billion$42.98 million-30.59News Coverage
Gap Up
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.8$48.17+6.5%$3.65 billionN/A-6.49Earnings Announcement
Analyst Report
News Coverage
Gap Up
Insmed logo
INSM
Insmed
1.2$35.77+3.9%$3.64 billion$136.47 million-13.76Earnings Announcement
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$27.18+1.1%$3.59 billion$64.39 million0.00Increase in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$124.96+3.3%$3.35 billionN/A-62.17Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$47.44+6.0%$3.29 billion$117.91 million-9.62Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
MorphoSys logo
MOR
MorphoSys
0.4$24.85+2.9%$3.27 billion$80.43 million118.34News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$12.28+2.9%$3.20 billion$182.24 million-10.68Upcoming Earnings
Gap Up
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$73.50+1.3%$3.19 billion$421.03 million25.88Earnings Announcement
Analyst Report
News Coverage
Gap Down
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$55.58+6.7%$3.07 billionN/A-30.54Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Alkermes logo
ALKS
Alkermes
1.2$19.04+2.1%$3.03 billion$1.17 billion-41.39Gap Down
OPKO Health logo
OPK
OPKO Health
1.9$4.50+1.8%$3.02 billion$901.90 million-25.00Gap Down
ALX Oncology logo
ALXO
ALX Oncology
2.1$80.29+3.0%$2.98 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$25.15+1.6%$2.95 billion$306.49 million28.26Earnings Announcement
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.20+0.5%$2.92 billion$50 million-7.58Upcoming Earnings
Decrease in Short Interest
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$35.43+0.7%$2.84 billion$60,000.00-11.00Earnings Announcement
Insider Selling
News Coverage
Gap Up
Xencor logo
XNCR
Xencor
1.0$49.27+5.1%$2.83 billion$156.70 million-35.19Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$71.50+0.5%$2.74 billion$644.77 million-10.20Increase in Short Interest
PRLD
Prelude Therapeutics
1.0$62.33+3.2%$2.72 billionN/A0.00Upcoming Earnings
News Coverage
Gap Down
IGMS
IGM Biosciences
1.5$87.43+4.0%$2.68 billionN/A-37.20Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$42.60+2.1%$2.63 billion$2.11 million-9.22Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$6.74+3.1%$2.62 billion$429.76 million-134.77Earnings Announcement
News Coverage
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.78+2.7%$2.52 billion$25 million-8.76
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$67.36+1.5%$2.52 billionN/A-25.04Upcoming Earnings
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.22+1.3%$2.38 billion$120.28 million-149.72Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.3$59.44+0.3%$2.36 billion$33.94 million-102.48Upcoming Earnings
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$35.26+2.9%$2.29 billion$15 million-18.46Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$41.71+0.1%$2.08 billion$963.01 million12.95
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.